title: Glucose lowering treatment in patients with coronary artery disease is prognostically important not only in established but also in newly detected diabetes mellitus: a report from the Euro Heart Survey on Diabetes and the Heart.
abstract: OBJECTIVE
  Glucose lowering (GL) therapy in patients with diabetes mellitus (DM) and coronary artery disease (CAD) is prognostically important. This report from the Euro Heart Survey on Diabetes and the Heart describes present practice in relation to 1 year prognosis.
  
  
  RESULTS
  The survey enrolled 4676 patients with CAD from 110 centres out of whom 1425 had known and 452 newly detected DM. The impact of different GL modalities on cardiovascular events (CVE: death, myocardial infarction, or stroke) was followed. Insulin treated patients with known DM (n = 378) had an adjusted 1 year hazard ratio (HR) for mortality of 2.23 (95% CI 1.24-4.03; P = 0.006) and for CVE of 1.27 (95% CI 0.85-1.87; P = 0.230) compared with those on oral GL drugs (n = 675). Of patients with newly detected DM 77 (17%) were started on GL drugs. None of them died compared with 25 (P = 0.002) among those without such treatment and their 1 year CVE HR was 0.22 (95% CI 0.05-0.97; P = 0.041) compared with untreated subjects.
  
  
  CONCLUSIONS
  Insulin therapy may relate to a more serious prognosis in CAD-patients with DM. There was a pronounced decrease in cardiovascular events in patients with newly detected DM prescribed GL drugs compared with those not receiving such treatment.
authors.affiliation: Department of Cardiology, San Giovanni Battista-Molinette-Hospital, Turin 10126, Italy.
authors.forename: Matteo
authors.initials: M
authors.lastname: Anselmino
authors.forename: John
authors.initials: J
authors.lastname: Ohrvik
authors.forename: Klas
authors.initials: K
authors.lastname: Malmberg
authors.forename: Eberhard
authors.initials: E
authors.lastname: Standl
authors.forename: Lars
authors.initials: L
authors.lastname: Rydén
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D003324:Coronary Artery Disease / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy* / Q000401:mortality; D003925:Diabetic Angiopathies / Q000097:blood / Q000401:mortality*; D004359:Drug Therapy, Combination; D005260:Female; D006306:Health Surveys; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007328:Insulin / Q000627:therapeutic use; D008297:Male; D008687:Metformin / Q000627:therapeutic use; D008875:Middle Aged; D011379:Prognosis; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D016019:Survival Analysis
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D013453:Sulfonylurea Compounds; D008687:Metformin